A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut+ acute myeloid leukemia in a U.S. health plan.
CONCLUSIONS: Adding gilteritinib to the formulary for the treatment of adults with R/R FLT3 mut+ AML had a minimal budget impact from a U.S. payer's perspective.
PMID: 33280474 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Economics | Health Management | Leukemia | Stem Cell Therapy | Stem Cells | Transplants